News
Video
Future Plans for the Evaluation of Ponatinib During the Ongoing OPTIC Trial
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.
Pharmacy Times® interviewed Hagop Kantarjian, MD, the professor and chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, on one of his presentations at the 62nd ASH Annual Meeting and Exposition. The presentation looks at the efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia who failed one or more second-generation tyrosine kinase inhibitors.
In this video, Kantarjian discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
